In a world where most medical conditions remain incurable, Roche aims to make a difference with treatments that are targeted to the needs of individuals.

Roche develops and delivers solutions that have the greatest impact on people's lives. At the forefront of the fight against cancer, Roche focuses on providing targeted treatment. Our therapies directly target the tumours of patients with breast cancer, gastrointestinal cancer, lung cancer and Non-Hodgkin's Lymphoma, a type of lymphatic cancer. Other treatments in our portfolio tackle the chronic fatigue and bone weakening that can further undermine the health and quality of life of people with cancer.

A major emerging therapy area for Roche is the management of osteoporosis, rheumatoid arthritis and other auto-immune related conditions.  Roche also leads in the field of viral diseases. Our scientists in the UK discovered the first protease inhibitor to combat HIV and we remain at the cutting edge in this field with the first of another new class of drugs, fusion inhibitors, which tackle HIV. The Hepatitis C and the influenza viruses pose a serious health risk in the UK, one that Roche helps clinicians address through our innovative therapies.